Bio-Techne Corporation, listed on NASDAQ under the ticker TECH, is a prominent developer and manufacturer of high-quality purified proteins, reagent solutions, and cell and gene therapy workflow technologies. The company serves a diverse range of clients, including academic institutions, biotechnology firms, and pharmaceutical companies, operating primarily in the life sciences and healthcare markets. Bio-Techne's business model revolves around the production and sale of essential biological products such as cytokines, growth factors, antibodies, immunoassays, and biologically active small molecule compounds. These products are crucial for scientific research and development, enabling advancements in areas like cancer research, immunology, and regenerative medicine. The company generates revenue through direct sales of its extensive product portfolio, which includes protein analysis solutions marketed under the ProteinSimple brand. Bio-Techne's financial performance is robust, with net sales reaching $738.7 million and operating income of $157.4 million for the fiscal year ending June 30, 2020. The company continues to innovate, recently launching a new SARS-CoV-2 Multi-Antigen Serology Assay Kit, further solidifying its position in the market.

Keywords: purified proteins, reagent solutions, cell therapy, cytokines, growth factors, antibodies, immunoassays, small molecule compounds, ProteinSimple, SARS-CoV-2 assay.